Thomas J. Schall insider trades: Immuneering (IMRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Thomas reports to the SEC
Open-market buys and sales
46 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 15, 2026 | IMRX | ↑ Buy | 21,645 | $4.67 | $101K | Direct | Jan 20, 2026 (5d) |
| Jun 27, 2025 | IMRX | ↑ Buy | 9,500 | $3.66 | $35K | Direct | Jun 30, 2025 (3d) |
| Jun 17, 2025 | IMRX | ↑ Buy | 40,485 | $2.21 | $89K | Direct | Jun 18, 2025 (1d) |
| Mar 22, 2024 | IMRX | ↑ Buy | 2,900 | $2.55 | $7K | Direct | Mar 25, 2024 (3d) |
| Aug 4, 2022 | CCXI | ↓ Sell | 130,000 | $50.24 | $6.5M | Direct | Aug 8, 2022 (4d) |
| Dec 15, 2020 | CCXI | ↓ Sell | 28,772 | $65.02 | $1.9M | Direct | Dec 16, 2020 (1d) |
| Jun 15, 2020 | CCXI | ↓ Sell | 90,753 | $65.08 | $5.9M | Direct | Jun 16, 2020 (1d) |
| May 12, 2020 | CCXI | ↓ Sell | 110,674 | $56.22 | $6.2M | Direct | May 12, 2020 (0d) |
| May 5, 2020 | CCXI | ↓ Sell | 8,851 | $55.01 | $487K | Direct | May 7, 2020 (2d) |
| Mar 4, 2020 | CCXI | ↓ Sell | 40,844 | $50.35 | $2.1M | Direct | Mar 5, 2020 (1d) |
| Feb 20, 2020 | CCXI | ↓ Sell | 78,681 | $50.44 | $4.0M | Direct | Feb 21, 2020 (1d) |
| Feb 4, 2020 | CCXI | ↓ Sell | 119,525 | $45.18 | $5.4M | Direct | Feb 6, 2020 (2d) |
| Jan 17, 2020 | CCXI | ↓ Sell | 136,052 | $41.47 | $5.6M | Direct | Jan 17, 2020 (0d) |
| Nov 26, 2019 | CCXI | ↓ Sell | 279,166 | $31.55 | $8.8M | Direct | Nov 27, 2019 (1d) |
| Apr 2, 2019 | CCXI | ↓ Sell10b5-1 | 160,000 | $13.72 | $2.2M | Direct | Apr 2, 2019 (0d) |
| Jan 10, 2019 | CCXI | ↓ Sell10b5-1 | 36,762 | $12.16 | $447K | Direct | Jan 14, 2019 (4d) |
| Jan 9, 2019 | CCXI | ↓ Sell10b5-1 | 20,170 | $12.02 | $242K | Direct | Jan 9, 2019 (0d) |
| Nov 7, 2018 | CCXI | ↓ Sell10b5-1 | 7,211 | $12.00 | $87K | Direct | Nov 9, 2018 (2d) |
| Jun 29, 2018 | CCXI | ↓ Sell10b5-1 | 10,857 | $14.00 | $152K | Direct | Jul 2, 2018 (3d) |
| May 23, 2018 | CCXI | ↓ Sell10b5-1 | 92,798 | $12.84 | $1.2M | Direct | May 23, 2018 (0d) |
| May 17, 2018 | CCXI | ↓ Sell10b5-1 | 200,000 | $11.78 | $2.4M | Direct | May 17, 2018 (0d) |
| May 2, 2018 | CCXI | ↓ Sell10b5-1 | 50,000 | $11.02 | $551K | Direct | May 3, 2018 (1d) |
| Apr 1, 2015 | CCXI | ↓ Sell | 24,267 | $7.50 | $182K | Direct | Apr 1, 2015 (0d) |
| Mar 25, 2015 | CCXI | ↓ Sell | 900 | $7.57 | $7K | Direct | Mar 27, 2015 (2d) |
| Mar 24, 2015 | CCXI | ↓ Sell | 50,371 | $7.84 | $395K | Direct | Mar 24, 2015 (0d) |
| Mar 19, 2015 | CCXI | ↓ Sell | 18,146 | $8.34 | $151K | Direct | Mar 20, 2015 (1d) |
| Mar 17, 2015 | CCXI | ↓ Sell | 31,316 | $8.55 | $268K | Direct | Mar 18, 2015 (1d) |
| May 1, 2014 | CCXI | ↓ Sell | 27,726 | $5.59 | $155K | Direct | May 2, 2014 (1d) |
| Apr 29, 2014 | CCXI | ↓ Sell | 32,274 | $5.38 | $174K | Direct | Apr 30, 2014 (1d) |
| Mar 17, 2014 | CCXI | ↓ Sell | 20,000 | $7.25 | $145K | Direct | Mar 19, 2014 (2d) |
| Feb 18, 2014 | CCXI | ↓ Sell | 20,000 | $7.05 | $141K | Direct | Feb 20, 2014 (2d) |
| Jul 16, 2013 | CCXI | ↓ Sell | 22,089 | $14.39 | $318K | Direct | Jul 17, 2013 (1d) |
| Jul 1, 2013 | CCXI | ↓ Sell | 311 | $14.50 | $5K | Direct | Jul 3, 2013 (2d) |
| May 15, 2013 | CCXI | ↓ Sell | 7,600 | $14.04 | $107K | Direct | May 17, 2013 (2d) |
| Apr 11, 2013 | CCXI | ↓ Sell | 2,529 | $14.02 | $35K | Direct | Apr 12, 2013 (1d) |
| Apr 2, 2013 | CCXI | ↓ Sell | 756 | $14.00 | $11K | Direct | Apr 2, 2013 (0d) |
| Mar 18, 2013 | CCXI | ↓ Sell | 16,801 | $14.10 | $237K | Direct | Mar 19, 2013 (1d) |
| Mar 14, 2013 | CCXI | ↓ Sell | 4,905 | $14.00 | $69K | Direct | Mar 14, 2013 (0d) |
| Mar 11, 2013 | CCXI | ↓ Sell | 6,948 | $14.00 | $97K | Direct | Mar 11, 2013 (0d) |
| Mar 6, 2013 | CCXI | ↓ Sell | 5,541 | $14.01 | $78K | Direct | Mar 6, 2013 (0d) |
| Mar 1, 2013 | CCXI | ↓ Sell | 15,000 | $13.61 | $204K | Direct | Mar 1, 2013 (0d) |
| Feb 22, 2013 | CCXI | ↓ Sell | 7,500 | $12.06 | $90K | Direct | Feb 26, 2013 (4d) |
| Nov 20, 2012 | CCXI | ↓ Sell | 2,100 | $12.01 | $25K | Direct | Nov 21, 2012 (1d) |
| Nov 16, 2012 | CCXI | ↓ Sell | 20,400 | $12.58 | $257K | Direct | Nov 16, 2012 (0d) |
| Nov 6, 2012 | CCXI | ↓ Sell | 22,500 | $12.01 | $270K | Direct | Nov 8, 2012 (2d) |
| Oct 1, 2012 | CCXI | ↓ Sell | 15,000 | $11.53 | $173K | Direct | Oct 3, 2012 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other IMRX insiders
Open-market trades in the last 12 months
About Thomas J. Schall's insider trades
Thomas J. Schall is a director at Immuneering (IMRX). Since Oct 1, 2012, Thomas has reported 4 open-market purchases worth $232K and 42 sales worth $57.7M on SEC Form 4. In the last 12 months: 1 buy ($101K).
8 sales (13% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include option exercises (34 filings), grants and awards (16 filings), shares withheld for taxes (6 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.